Volume 75, Issue 2 , Pages 343-347, 1 October 2009
Survey of Stereotactic Body Radiation Therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group
Purpose
To recognize the current status of stereotactic body radiotherapy (SBRT) in Japan, using a nationwide survey conducted by the Japan 3-D Conformal External Beam Radiotherapy Group.
Methods and Materials
The questionnaire was sent by mail to 117 institutions. Ninety-four institutions (80%) responded by the end of November 2005. Fifty-three institutions indicated that they have already started SBRT, and 38 institutions had been reimbursed by insurance.
Results
A total of 1111 patients with histologically confirmed lung cancer were treated. Among these patients, 637 had T1N0M0 and 272 had T2N0M0 lung cancer. Metastatic lung cancer was found in 702 and histologically unconfirmed lung tumor in 291 patients. Primary liver cancer was found in 207 and metastatic liver cancer in 76 patients. The most frequent schedule used for primary lung cancer was 48Gy in 4 fractions at 22 institutions (52%), followed by 50Gy in 5 fractions at 11 institutions (26%) and 60Gy in 8 fractions at 4 institutions (10%). The tendency was the same for metastatic lung cancer. The average number of personnel involved in SBRT was 1.8 radiation oncologists, including 1.1 certified radiation oncologists, 2.8 technologists, 0.7 nurses, and 0.6 certified quality assurance personnel and 0.3 physicists. The most frequent amount of time for treatment planning was 61–120min, for quality assurance was 50–60min, and for treatment was 30min. There were 14 (0.6% of all cases) reported Grade 5 complications: 11 cases of radiation pneumonitis, 2 cases of hemoptysis, and 1 case of radiation esophagitis.
Conclusion
The current status of SBRT in Japan was surveyed.
SBRT, Survey, Stereotactic radiotherapy, Lung cancer, Liver cancer
To access this article, please choose from the options below
Presented in part at the 5th Japan/US Cancer Therapy Symposium and the 5th Shinji Takahashi Memorial Joint Symposium, September 7–9, 2007, Sendai, Japan; and at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, November 5–9, 2006, Denver, Colorado.
The following institutes in Japan participated in this survey: National Defense Medical College, Yamanashi University, Tohoku University, Keio University, Osaka Rosai Hospital, Hokkaido University, Yamagata Saiseikan Hospital, Hiroshima University, Tokyo Metropolitan Hiroo Hospital, Oita National Hospital, Asahikawa Municipal Hospital, Kitazato University, Tokyo University, Nara Medical College, Kagoshima Satunan Hospital, Kobe IBRI Hospital, Saitama Medical College, NTT East Sapporo Hospital, Gifu University, Hakodate Municipal Hospital, Ibaraki Prefectural Central Hospital, Obihiro Kosei Hospital, Mie University, Chiba Cancer Center, Showa University, Kyushu University, Hyogo Medical Center for Adults, Nagasaki Prefectural Shimabara Hospital, Sapporo Municipal Hospital, Fukui Red Cross Hospital, Kameda General Hospital, Yamaguchi University, Daiyukai General Hospital, Musashino Red Cross Hospital, Hokkaido Cancer Center, Sapporo Medical College, Nihon University, Handa Municipal Hospital, Tenri Hospital, Saitama Cancer Center, Tokyo Medical College Hachioji Center, Aichi Cancer Center, Hiroshima Red Cross Hospital, Kobe University, Kashiwabara General Hospital, Hitachi General Hospital, Hirosaki University, Iwate Tanzawa Hospital, Sendai Kosei Hospital, Furukawa Municipal Hospital, Takeda General Hospital, Tokyo Metropolitan Komagome Hospital, Nagaoka Red Cross Hospital, Fukui University, Hiroshima Prefectural Hospital, Tokushima University, Kagawa University, Kumamoto University, West Kobe Medical Center, Jyuntendo University Hospital, Osaka Medical College, Asahikawa Kohsei Hospital, Gunma University, Japan Defense Structure Central Hospital, St. Luke's International Hospital, Maebashi Red Cross Hospital, Sagamihara Kyodo Hospital, Toyama Municipal Hospital, Shizuoka Saiseikai Hospital, Shiga University, Rinku Central Medical Center, Kurume University, Niigata Cancer Center, Aichi Medical College, Asanokawa General Hospital, Ehime University, Osaka University, Osaka City University, Osaka Red Cross Hospital, Osaka Medical Center for Cancer, Okayama University, Nagoya Second Red Cross Hospital, Kanazawa University, Kawasaki Medical College, Nagoya City University, Nagoya University, The Cancer Institute Hospital, Gifu Prefectural Hospital, Yokohama Municipal Hospital, Kyushu Cardiovascular Center, Kinki University, Konan St. Hill Hospital, National Cancer Center Hospital, National Cancer Center Hospital East, National Kure Hospital, Saga University, Shikoku Cancer Center, Shizuoka Cancer Center, Yokohama Rosai Hospital, Shizuoka General Hospital, Jichi University, JA Hiroshima General Hospital, Yamagata University, St. Marianna University, Seirei Hamamatsu General Hospital, Teikyo University, Tokai University, Tokyo Medical University, Tokyo Women's Medical University, Toyohashi Municipal Hospital, Nagasaki University, Nagoya National Hospital, and Kyoto University.
Conflict of interest: none.
PII: S0360-3016(09)00852-9
doi:10.1016/j.ijrobp.2009.02.087
© 2009 Elsevier Inc. All rights reserved.
Volume 75, Issue 2 , Pages 343-347, 1 October 2009
